Scientific Publications
-
July 8, 2025A Potent GalNAc-siRNA Drug, RBD1016, Leads to Sustained HBsAg Reduction and Seroconversion in Mouse Models of HBV infection
DOI: 10.1016/j.omtn.2025.102627
-
February 19, 2025Inhibition of Factor XI Using RBD4059: A Novel GalNAc-siRNA With Potent and Durable Antithrombotic Effects
DOI: 10.1016/j.jacbts.2024.12.005
-
October 29, 2024GalNAc-Conjugated siRNA Targeting Complement C3 Inhibits Osteoclast Activation in Periodontitis
DOI: 10.1111/odi.15170
-
August 19, 2024The efficacy and safety of ISIS 449884 injection as monotherapy in patients with type 2 diabetes: A randomized phase II study
DOI: 10.1111/dom.15862
-
July 15, 2024ISIS 449884 Injection Add‑On to Metformin in Patients with Type 2 Diabetes: A Randomized, Double‑Blind, Placebo‑Controlled, Phase II Clinical Study
DOI: 10.1007/s13300-024-01617-3
-
May 24, 2024Analysis of the pharmacokinetics and efficacy of RBD1016 – A GalNAc-siRNA targeting Hepatitis B Virus X gene using semi-mechanistic PK/PD model
DOI: 10.1016/j.heliyon.2024.e31924